Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sleep apnea may signal hidden liver trouble

NCT ID NCT07716995

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study investigates whether obstructive sleep apnea is linked to metabolic associated fatty liver disease (MAFLD) in adults. Researchers will measure sleep apnea severity using overnight sleep tests and liver fat using a special ultrasound-like scan. The goal is to see if worse sleep apnea is tied to more liver fat buildup.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If a strong link is found, it could lead to better screening and management of fatty liver disease in people with sleep apnea.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The results may not apply to everyone with these conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 127 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* Patients with a clinical suspicion of sleep-disordered breathing will undergo overnight polysomnography and the followings indices will be recorded(apnea-hypopnea index (AHI); oxygen desaturation index (ODI); lowest arterial oxyhemoglobin saturation during sleep(LaSO2); mean arterial oxyhemoglobin saturation during sleep(mean SpO2); and %sleep time in which SpO2 \< 90%.( TS90%). * Diagnosis of MAFLD will made when a patient has BMI \>25 kg/m2, T2DM or at least two metabolic risk abnormalities. * All patients will undergo data pertaining to clinical history (name, age, sex, residence, occupation, co-morbidities… diabetes, hyperlipidemia, hypertension, ischemic heart disease, special habits; such as alcohol intake and smoking). * Four anthropometric measurements will be obtained (height, weight, body mass index, waist circumference (WC)). * Blood samples will be collected for doing liver function tests, lipid profile, CBC, HbA1c.

Ages

18 to 60 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged \>18 years old * presented with a clinical suspicion of sleep-disordered breathing, including snoring, sleepiness and witnessed sleep apnea Exclusion Criteria: * Patients aged ≤18 years old * Pregnancy * Presence of malignancy * Type I DM * Patients with fatty liver who undergone bariatric surgeries. * Patients with Central sleep apnea, upper airway resistance and narcolepsy * Patients with lung diseases with hypoxia * Previous history of alcohol consumption, steroids, proton pump inhibitors, antibiotics, and contraceptive pills

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic associated fatty liver disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease obstructive sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic dysfunction-associated steatotic liver disease Obstructive sleep apnea OSA association with mafld

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.